A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Inclusion Criteria: For Parts A, B, and C: * Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types: * High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer * HER2-negative, HR positive breast cancer * Triple-negative breast cancer (TNBC) * Endometrial carcinoma * Non-small cell lung cancer (Squamous cell carcinoma \[SqCC\], Adenocarcinoma \[AC\]) * Cholangiocarcinoma or gallbladder carcinoma * Adenoid cystic carcinoma (ACC) For Part D: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC. For Part E: * Cohort E1: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC and must have CPS≥10 by local testing * Cohort E2: Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic TNBC and must have CPS\<10 by local testing * Cohort E3: Participants must have triple negative breast cancer with residual disease following neoadjuvant therapy and definitive surgery * Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option * Part C: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies. * Part D and E1/E2: Participants must have had no prior treatment for locally advanced unresectable or metastatic TNBC * Part E3: Participants must have completed at least 6 cycles of neoadjuvant therapy for locally advanced unresectable or metastatic TNBC * Tumor tissue is required for enrollment. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Measurable disease per RECIST version 1.1 at baseline (not applicable for E3 participants). Exclusion Criteria: * History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death. * Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they: * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment * have no new or enlarging brain metastases * and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment. * Carcinomatous meningitis * Previous receipt of an MMAE-containing agent or an agent targeting B7-H4 * Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 * Corneal disease or injury requiring treatment or active monitoring